Friday, 16 October 2026European Markets

KOMPLETT BANK Stock Is 11% Up So Far On Tuesday

Loading stream...

(VIANEWS) - Shares of KOMPLETT BANK (Oslo Børs Benchmark Index_GI: KOMP.OL) rose by a staggering 11.49% to kr5.24 at 11:38 EST on Tuesday, following the last session's downward trend. Oslo Børs Benchmark Index_GI is sliding 0.49% to kr1,213.86, following the last session's upward trend. This seems, up to now, a somewhat down trend exchanging session today.

KOMPLETT BANK's last close was kr4.70, 38.16% under its 52-week high of kr7.60.

About KOMPLETT BANK

Komplett Bank ASA provides unsecured financing to private individuals in the Norwegian, Finland, Sweden, and German markets. It offers deposit products, consumer loans, credit cards, and point of sale finance products. Komplett Bank ASA was incorporated in 2012 and is headquartered in Lysaker, Norway.

Earnings Per Share

As for profitability, KOMPLETT BANK has a trailing twelve months EPS of kr-0.07.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 0.05%.

Volatility

KOMPLETT BANK's last week, last month's, and last quarter's current intraday variation average was 0.11%, 0.12%, and 1.56%.

KOMPLETT BANK's highest amplitude of average volatility was 0.75% (last week), 1.00% (last month), and 1.56% (last quarter).

Volume

Today's last reported volume for KOMPLETT BANK is 66664 which is 40.05% below its average volume of 111201.

More news about KOMPLETT BANK (KOMP.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com